Q3 2022 13F Holders as of 30 Sep 2022
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
77,143,980
-
Number of holders
-
114
-
Total 13F shares, excl. options
-
43,069,388
-
Shares change
-
-3,045,007
-
Total reported value, excl. options
-
$561,182,776
-
Value change
-
-$38,324,545
-
Number of buys
-
68
-
Number of sells
-
-30
-
Price
-
$13.03
Significant Holders of Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share (NRIX) as of Q3 2022
124 filings reported holding NRIX - Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q3 2022.
Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share (NRIX) has 114 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 43,069,388 shares
of 77,143,980 outstanding shares and own 56% of the company stock.
Largest 10 shareholders include BAKER BROS. ADVISORS LP (3,882,125 shares), BlackRock Inc. (3,723,090 shares), PRICE T ROWE ASSOCIATES INC /MD/ (3,606,352 shares), Redmile Group, LLC (3,006,684 shares), WASATCH ADVISORS INC (2,657,437 shares), STATE STREET CORP (2,312,224 shares), VANGUARD GROUP INC (2,160,866 shares), Deep Track Capital, LP (2,053,621 shares), Bain Capital Life Sciences Investors, LLC (1,822,883 shares), and FMR LLC (1,685,651 shares).
This table shows the top 114 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.